FDA recognized this disconnect and issued its Computer Software Assurance (CSA) draft guidance in 2022, formally replacing the earlier General Principles of Software Validation guidance from 2002. CSA does not eliminate computer system validation. It redirects validation effort toward activities that meaningfully reduce risk rather than toward documentation volume that satisfies auditors but protects no one.

This guide covers what CSA requires, how it differs from traditional computer system validation (CSV), and how to implement a risk-based validation program that satisfies FDA while reducing the burden on quality teams.

What CSA is and what changed from the 2002 guidance

The FDA’s 2022 CSA draft guidance establishes a risk-based framework for assuring that computer systems used in regulated pharmaceutical and device manufacturing perform as intended. The core shift is this: validation effort should be proportional to the patient risk associated with the system, and it should focus on critical thinking and testing rather than on producing documentation for its own sake.

Under the old 2002 guidance, organizations interpreted “validation” as a documentation exercise. The common result was validation packages with thousands of pages of pre-approved test scripts, executed line by line, generating execution records that demonstrated procedure-following but rarely uncovered actual system defects. CSA frames this as wasted effort that could more productively go toward genuine risk analysis and targeted testing of functions that matter.

The 2022 CSA guidance introduces several important concepts:

• Intended use drives scope: Validation scope is defined by how the system is used in your regulated context, not by all features the software contains. A laboratory information management system used only to track sample status requires validation of the sample tracking function, not every feature in the software.
• Supplier leverage is expected: Organizations are expected to leverage supplier documentation, testing, and quality evidence rather than repeating all testing themselves. Supplier audit results, software development lifecycle documentation, and factory acceptance testing records all contribute to your validation evidence.
• Testing should be risk-based and scripted versus unscripted based on risk: High-risk functions require scripted, pre-approved testing with recorded execution. Lower-risk functions may be verified through unscripted exploratory testing by qualified users, which FDA explicitly permits under CSA.
• Audit trails remain non-negotiable: Regardless of system risk level, any system that creates, modifies, or deletes regulated records must maintain a complete audit trail. CSA does not relax 21 CFR Part 11 requirements.

The CSA risk-based framework in practice

Implementing CSA requires applying structured risk thinking at two levels: system-level categorization and function-level risk assessment.

System-level categorization

The first step in a CSA-based validation program is categorizing each computer system based on its intended use and its connection to patient risk. FDA’s guidance distinguishes between systems that directly affect product quality and patient safety, systems that create or manage regulated records, and systems that are used in regulated operations but have limited direct patient risk impact.

A manufacturing execution system that controls process parameters in a GMP batch is a high-risk system. An inventory management system used to track non-critical office supplies is not subject to validation at all. A quality management system that stores batch records and deviation investigations falls in between, with specific functions (audit trail, access control, record integrity) requiring documented validation evidence and lower-risk features requiring less.

Function-level risk assessment

Once the system category is established, the validation team identifies the specific functions used in regulated activities and assigns a risk rating to each. The risk rating is based on three questions: What is the probability that this function will fail? If it fails, what is the severity of the impact on product quality or patient safety? Is there a detection mechanism that would catch the failure before it affects regulated activities?

Functions rated high risk require scripted, pre-approved test protocols executed by qualified testers with recorded results. Functions rated low risk can be verified through unscripted testing or by leveraging supplier qualification evidence. Functions that are not used in regulated activities are out of scope entirely.

Step-by-step CSA implementation

Step 1: Define the intended use

Write a clear intended use statement for the system that describes what it does, who uses it, and how it connects to regulated activities. This statement defines the scope of everything that follows. If the intended use is defined too broadly, the validation becomes unnecessarily large. If it is too narrow, FDA may ask about functions that were excluded without justification.

Step 2: Identify and evaluate the supplier

Evaluate the software supplier’s development practices, testing documentation, and quality management system. A supplier with a mature software development lifecycle and comprehensive factory acceptance testing documentation provides evidence you can use directly in your validation package, reducing the amount of testing your organization needs to perform. Document your supplier evaluation with the criteria used and the conclusions reached.

Step 3: Conduct a system risk assessment

Perform a risk assessment at the function level, documenting each function, its intended use in your regulated context, the risk rating, and the rationale for that rating. This risk assessment is the backbone of the entire validation program. It determines which functions get scripted testing, which get unscripted testing, and which rely primarily on supplier evidence.

Step 4: Develop a validation plan

The validation plan describes the scope, approach, roles and responsibilities, and deliverables for the validation. Under CSA, the plan should explicitly state which functions are in scope, which testing approach applies to each (scripted vs. unscripted), what supplier evidence will be leveraged, and how validation will be maintained over the system’s lifecycle.

Step 5: Execute testing appropriate to the risk level

Execute scripted protocols for high-risk functions. Protocols must be pre-approved before execution, executed by qualified personnel, and deviations from the protocol must be documented and resolved before the protocol is closed. For low-risk functions, perform unscripted testing by qualified users who document what they tested and the results they observed. Capture screenshots, system-generated logs, or other objective evidence of testing.

Step 6: Manage deviations and failures

Any deviation from a scripted test protocol or any failure observed during unscripted testing must be documented, assessed for patient risk impact, and resolved before the system is accepted for regulated use. Resolution may require working with the supplier to correct a defect, or it may involve a workaround and a documented risk acceptance if the issue is minor and the risk is acceptably low.

Step 7: Complete the validation summary and accept the system

The validation summary consolidates all evidence gathered — supplier qualification, risk assessment, test execution records, deviation resolutions — and documents the conclusion that the system is suitable for its intended use. This document, signed by the validation team and quality unit, formally accepts the system for regulated use.

Step 8: Maintain validation through the system’s lifecycle

CSA does not end at initial deployment. Changes to the system, its configuration, or its intended use trigger a change control process that evaluates whether revalidation is required and to what extent. Periodic reviews confirm that the system continues to perform as intended. Audit trail reviews should be scheduled and documented on a defined frequency.

Common CSA implementation mistakes

Treating CSA as a documentation reduction exercise only. CSA reduces unnecessary documentation, but it increases the expectation that the documentation that does exist is genuinely thoughtful. Risk assessments that assign every function a “medium” risk without clear rationale, or validation plans that repeat boilerplate language without connecting it to the specific system and intended use, will not satisfy FDA reviewers.

Underestimating supplier qualification requirements. Leveraging supplier evidence requires actually evaluating the supplier’s quality system and documentation. A supplier qualification that consists of downloading a certificate from the vendor’s website is insufficient. The evaluation must assess development practices, testing rigor, and the supplier’s own quality management.

Forgetting legacy systems. CSA applies to new systems. Organizations with legacy systems validated under the old approach do not need to retroactively revalidate using CSA, but any significant changes to those systems should be managed using risk-based CSA principles going forward.

How Cloudtheapp supports computer system validation

Cloudtheapp is built on a fully validated platform that includes a comprehensive validation package for every software update, delivered to customers at no additional cost. The platform conforms to FDA computer system validation guidelines and provides the IQ, OQ, and PQ documentation that regulated manufacturers need to support their own validation activities.

For organizations managing their internal computer system validation program, Cloudtheapp’s quality management suite includes validation management workflows that support the CSA framework: risk assessments, test protocol authoring and execution tracking, deviation management, and validation summary generation. With 60+ applications and a no-code configuration environment, Cloudtheapp can be adapted to match your specific validation SOPs without custom software development. Schedule a demo to see the validation management capabilities in practice.

Conclusion

FDA’s CSA guidance does not make computer system validation optional. It makes it smarter. By focusing validation effort on the functions that actually matter for patient safety and product quality, and by explicitly permitting organizations to leverage supplier evidence and unscripted testing for lower-risk functions, CSA allows quality teams to spend less time generating paper and more time doing the risk thinking that genuine quality assurance requires. Organizations that implement CSA well will find that their validation packages are smaller, more defensible, and faster to complete than anything produced under the old documentation-first approach.

This post created by and appeared first on Cloudtheapp